06-1086 | Anti-TGF-beta Receptor Antibody, type I

06-1086
100 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, Eq, R, Op, Po, B, CaWB, IH(P)RbAffinity PurifiedPolyclonal Antibody
      Description
      Catalogue Number06-1086
      DescriptionAnti-TGF-beta Receptor Antibody, type I
      Alternate Names
      • TGF-beta receptor type-1
      • Transforming growth factor-beta receptor type I
      • TGF-beta receptor type I
      • TGF-beta type I receptor
      • Serine/threonine-protein kinase receptor R4
      • Activin receptor-like kinase 5
      Background InformationTransforming growth factor, beta receptor type I (TGF-beta receptor I) forms a heteromeric complex with TGF-beta receptor type II when bound to TGF-beta. This complex transduces the TGF-beta signal from the cell surface to the cytoplasm. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. TGF-beta receptor I is found in all tissues, but is most abundant in placenta and least abundant in brain and heart tissue. TGF-beta receptor I is phosphorylated at basal levels in the absence of ligand binding and is multiply phosphorylated, mainly in the GS region. Defects in TGF-beta receptor I are the cause of Loeys-Dietz syndrome type 1A (LDS1A), also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS) (Uniprot/Swissprot).
      References
      Product Information
      FormatAffinity Purified
      Control
      • HepG2 cell lysate, mouse spleen tissue
      PresentationPurified rabbit polyclonal in PBS with 0.06% sodium azide.
      Applications
      ApplicationThis Anti-TGF-beta Receptor Antibody, type I is validated for use in WB, IH(P) for the detection of TGF-beta Receptor.
      Key Applications
      • Western Blotting
      • Immunohistochemistry (Paraffin)
      Application NotesImmunohistochemistry (paraffin) Analysis: A 1:100 dilution of a previous lot was used to detect TGF-beta receptor, type I in mouse spleen tissue.
      Optimal Staining With Citrate pH 6.0 Epitope Retrieval: Mouse Spleen
      Biological Information
      ImmunogenKLH-conjugated linear peptide corresponding to the cytoplasmic domain of TGF-beta receptor, type-I.
      EpitopeCytoplasmic Domain
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostRabbit
      SpecificityAntibody recognizes the cytoplasmic domain of TGF-beta receptor, type-I.
      Species Reactivity
      • Human
      • Mouse
      • Horse
      • Rat
      • Opossum
      • Pig
      • Bovine
      • Canine
      Species Reactivity NoteDemonstrated to react with human and mouse.
      Predicted to react with horse, rat, opossum, pig, bovine and canine based on 100% sequence homology.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryActivins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type IB receptor, composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed. [provided by RefSeq]
      Gene Symbol
      • TbetaR-I
      • TGFBR1
      • TGFR-1
      • SKR4
      • ALK-5
      Purification MethodAffinity Purfied
      UniProt Number
      UniProt SummaryFUNCTION: On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta.

      CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-protein] phosphate.

      COFACTOR: Magnesium or manganese.

      SUBUNIT STRUCTURE: Interacts with CD109 and RBPMS. The unphosphorylated protein interacts with FKBP1A and is stabilized the inactive conformation. Phosphorylation of the GS region abrogates FKBP1A binding. Interacts with SMAD2 when phosphorylated on several residues in the GS region.

      SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.

      TISSUE SPECIFICITY: Found in all tissues examined, most abundant in placenta and least abundant in brain and heart.

      POST-TRANSLATIONAL MODIFICATION: Phosphorylated at basal levels in the absence of ligand binding. Activated by multiple phosphorylation, mainly in the GS region.

      INVOLVEMENT IN DISEASE: Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.

      Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients.

      Defects in TGFBR1 are the cause of aortic aneurysm familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance.



      SEQUENCE SIMILARITIES: Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.

      Contains 1 GS domain.

      Contains 1 protein kinase domain.
      Molecular Weight~56 kDa .
      Additional non-specific bands are observed in western blot at ~22 kDa and ~45 kDa.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blot in HepG2 cell lysate.

      Western Blot Analysis: 0.5 µg/mL of this antibody detected TGF-beta receptor, type I in 10 µg of HepG2 cell lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      SDS

      Title

      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-TGF-beta Receptor, type I - 2148283 2148283
      Anti-TGF-beta Receptor, type I - 2344723 2344723
      Anti-TGF-beta Receptor, type I - 2453395 2453395
      Anti-TGF-beta Receptor, type I - 2197272 2197272
      Anti-TGF-beta Receptor, type I - 2492784 2492784
      Anti-TGF-beta Receptor, type I - NG1836509 NG1836509
      Anti-TGF-beta Receptor, type I - NG1918612 NG1918612
      Anti-TGF-beta Receptor, type I - NRG1700060 NRG1700060

      References

      Reference overviewPub Med ID
      An in vitro culture system for long-term expansion of epithelial and mesenchymal salivary gland cells: role of TGF-β1 in salivary gland epithelial and mesenchymal differentiation.
      Janebodin, Kajohnkiart, et al.
      Biomed Res Int, 2013: 815895 (2013)  2013

      Show Abstract
      23841093 23841093
      CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms.
      Fang, WB; Jokar, I; Zou, A; Lambert, D; Dendukuri, P; Cheng, N
      The Journal of biological chemistry  287  36593-608  2012

      Show Abstract
      22927430 22927430

      Brochure

      Title
      Product Selection Guide - Antibodies, small molecule inhibitors, kits, assays and proteins for signaling research.